Cytena
Cytena develops single-cell printing technology for cell research and professional diagnostics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
€30.3m Valuation: €30.3m | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | 24 % | - | - | (26 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Cytena specializes in single cell dispensing technology, which significantly enhances cell line development, single cell omics, and microbiome workflows. The company operates in the biotechnology sector, serving clients such as pharmaceutical companies, research institutions, and biotech firms. Cytena's business model revolves around providing advanced instruments and solutions that ensure efficiency, accuracy, and proof of clonality in single cell applications. The company generates revenue through the sale of its patented dispensing instruments, as well as offering online demos, trainings, and workflow consultations. By leveraging automation and microtechnology, Cytena aims to empower its customers to achieve better results faster, ultimately improving patient care.
Keywords: single cell dispensing, cell line development, single cell omics, microbiome workflows, biotechnology, automation, microtechnology, pharmaceutical, research institutions, biotech firms.